Logo for LENZ Therapeutics Inc

LENZ Therapeutics Investor Relations Material

Latest events

Logo for LENZ Therapeutics Inc

Status Update

LENZ Therapeutics
Logo for LENZ Therapeutics

Status Update

15 Apr, 2025
Logo for LENZ Therapeutics

Q4 2024

19 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from LENZ Therapeutics Inc

Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.